Results 201 to 210 of about 696,028 (214)

Confirmatory versus explorative endpoint analysis: Decision-making on the basis of evidence available from market authorization and early benefit assessment for oncology drugs

Health Policy, 2018
Charalabos-Markos Dintsios
exaly  

Can Routine Data be used to Determine the Target Population of Patients with Type 2 Diabetes in Early Benefit Assessments in Germany?

Gesundheitswesen, 2020
Peter Ihle, Sarah Mostardt
exaly  

Application of the ESMO-Magnitude of Clinical Benefit Scale (V.1.1) to the field of early breast cancer therapies

ESMO Open, 2020
Nicola Jane Latino, Martine Piccart, Shani Paluch-Shimon   +2 more
exaly  

Effect of Crossover in Oncology Clinical Trials on Evidence Levels in Early Benefit Assessment in Germany

Value in Health, 2018
Joerg Ruof, Charalabos-Markos Dintsios, Volker Eric Amelung   +2 more
exaly  

Randomized trials addressing a similar question are commonly published after a trial stopped early for benefit

Journal of Clinical Epidemiology, 2017
Robin W M Vernooij, Jason Busse, Joerg J Meerpohl   +2 more
exaly  

Early benefit assessment of new drugs in Germany – Results from 2011 to 2012

Health Policy, 2014
Beate Wieseler, Natalie Mcgauran
exaly  

BENEFIT OF CLINICAL TRIALS TO PARTICIPANTS QUESTIONED

Ca-A Cancer Journal for Clinicians, 2004
exaly  

WIDER BENEFIT FOUND FOR SALVAGE RADIOTHERAPY AFTER PROSTATECTOMY

Ca-A Cancer Journal for Clinicians, 2004
exaly  

STUDY CONFIRMS SURVIVAL BENEFIT FROM ADJUVANT RADIATION FOR BREAST CANCER

Ca-A Cancer Journal for Clinicians, 2006
exaly  

ACS EXPERT DISPUTES METHODOLOGY OF STUDY QUESTIONING MAMMOGRAPHY BENEFIT

Ca-A Cancer Journal for Clinicians, 2005
exaly